COVID-19 trials registries data warehouse

 Return to trial list

Trial - NCT04377711


Column Value
Trial registration number NCT04377711
Full text link
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

First author
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

Covis Pharma S.à.r.l.

Contact
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

Dr Clemency, bc34@buffalo.edu (PI email not reported)

Registration date
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

2020-05-06

Recruitment status
Last imported at : April 16, 2021, 12:31 a.m.
Source : ClinicalTrials.gov

Completed

Study design
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

RCT

Allocation
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

Randomized

Design
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

Parallel

Masking
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

Blind label

Center
Last imported at : March 15, 2023, 4 a.m.
Source : ClinicalTrials.gov

single-center

Study aim
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

Treatment

Inclusion criteria
Last imported at : Nov. 16, 2021, 6:30 p.m.
Source : ClinicalTrials.gov

inclusion criteria patients eligible for enrollment in the study must meet all the following criteria: male and female adults and adolescents (12 years of age and above). positive sars-cov-2 rapid molecular diagnostic test within 72 hours prior to enrollment. patient is not currently hospitalized or under immediate consideration for hospitalization at the time of enrollment. patient is currently experiencing symptoms of fever, cough, and/or dyspnea. patient has an oxygen saturation level greater than 93%. ability to show adequate use of mdi, including inhalation technique. patient, parent/legal guardian, or legally-authorized representative must have signed a written informed consent before administration of any study-specific procedures. exclusion criteria patients meeting any of the following criteria are not eligible for participation in the study: existence of any life-threatening co-morbidity or any other medical condition which, in the opinion of the investigator, makes the patient unsuitable for inclusion. history of hypersensitivity to ciclesonide. treatment with inhaled or intranasal corticosteroids within 14 days of the screening/ enrollment/randomization visit. treatment with oral corticosteroids within 90 days of the screening/enrollment/randomization visit. participation in any other clinical trial or use of any investigational agent within 30 days of the screening/enrollment/randomization visit. currently receiving treatment with hydroxychloroquine/chloroquine. patients with cystic fibrosis. patients with idiopathic pulmonary fibrosis.

Exclusion criteria
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

None

Number of arms
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

2

Funding
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

Covis Pharma S.à.r.l.

Inclusion age min
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

12

Inclusion age max
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

100

Countries
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

United States

Type of patients
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

Mild disease at enrollment

Severity scale
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

1: Mild disease at enrollment

Total sample size
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

400

primary outcome
Last imported at : April 16, 2021, 12:31 a.m.
Source : ClinicalTrials.gov

Time to alleviation of COVID-19-related symptoms by Day 30

Notes
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

None

Phase
Last imported at : Feb. 25, 2021, 7:58 p.m.
Source : ClinicalTrials.gov

Phase 3

Arms
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov

[{"arm_notes": "", "treatment_id": 282, "treatment_name": "Ciclesonide", "treatment_type": "Corticosteroids", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]